Literature DB >> 16867030

Preclinical evidence of Alzheimer changes in progressive mild cognitive impairment: a qualitative and quantitative SPECT study.

A Ishiwata1, O Sakayori, S Minoshima, S Mizumura, S Kitamura, Y Katayama.   

Abstract

OBJECTIVES: Baseline brain single-photon emission computed tomography (SPECT) can predict mild cognitive impairment (MCI) patients at risk for progressive MCI (PMCI).
METHODS: Twenty-eight subjects [12 MCI, 6 with probable Alzheimer's Disease (AD), and 10 normal subjects] underwent baseline brain SPECT and were clinically followed for a mean period of 36 months.
RESULTS: Of 12 MCI patients, 6 progressed to PMCI and 6 remained stable. Baseline SPECT identified asymmetric perfusion reduction in the parahippocampus (-5%), lateral parietal (-8%), and posterior cingulate (-11%) cortices--reductions consistent with that of mild AD--in five of the six PMCI patients. Significant perfusion reduction was observed particularly in the frontal cortices of probable AD when compared with PMCI (P < 0.05).
CONCLUSION: Baseline SPECT can identify brain perfusion abnormalities among patients with MCI for progression to PMCI. This imaging modality may aid in MCI treatment stratification.

Entities:  

Mesh:

Year:  2006        PMID: 16867030     DOI: 10.1111/j.1600-0404.2006.00661.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  16 in total

Review 1.  Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue.

Authors:  Julio C Rojas; Aleksandra K Bruchey; F Gonzalez-Lima
Journal:  Prog Neurobiol       Date:  2011-11-03       Impact factor: 11.685

2.  Delayed Methylene Blue Improves Lesion Volume, Multi-Parametric Quantitative Magnetic Resonance Imaging Measurements, and Behavioral Outcome after Traumatic Brain Injury.

Authors:  Lora Talley Watts; Justin Alexander Long; Robert Cole Boggs; Hemanth Manga; Shiliang Huang; Qiang Shen; Timothy Q Duong
Journal:  J Neurotrauma       Date:  2015-08-13       Impact factor: 5.269

3.  ASL perfusion MRI predicts cognitive decline and conversion from MCI to dementia.

Authors:  Linda L Chao; Shannon T Buckley; John Kornak; Norbert Schuff; Catherine Madison; Kristine Yaffe; Bruce L Miller; Joel H Kramer; Michael W Weiner
Journal:  Alzheimer Dis Assoc Disord       Date:  2010 Jan-Mar       Impact factor: 2.703

4.  Cerebral perfusion correlates of conversion to Alzheimer's disease in amnestic mild cognitive impairment.

Authors:  A Caroli; C Testa; C Geroldi; F Nobili; L R Barnden; U P Guerra; M Bonetti; G B Frisoni
Journal:  J Neurol       Date:  2007-11-09       Impact factor: 4.849

5.  Brain SPECT in subtypes of mild cognitive impairment. Findings from the DESCRIPA multicenter study.

Authors:  Flavio Nobili; Giovanni B Frisoni; Florence Portet; Frans Verhey; Guido Rodriguez; Anna Caroli; Jacques Touchon; Piero Calvini; Silvia Morbelli; Fabrizio De Carli; Ugo P Guerra; Laura A Van de Pol; Pieter-Jelle Visser
Journal:  J Neurol       Date:  2008-08-01       Impact factor: 4.849

6.  Methylene blue potentiates stimulus-evoked fMRI responses and cerebral oxygen consumption during normoxia and hypoxia.

Authors:  Shiliang Huang; Fang Du; Yen-Yu I Shih; Qiang Shen; F Gonzalez-Lima; Timothy Q Duong
Journal:  Neuroimage       Date:  2013-01-26       Impact factor: 6.556

7.  Growth hormone-releasing hormone effects on brain γ-aminobutyric acid levels in mild cognitive impairment and healthy aging.

Authors:  Seth D Friedman; Laura D Baker; Soo Borson; J Eric Jensen; Suzanne M Barsness; Suzanne Craft; George R Merriam; Randolph K Otto; Edward J Novotny; Michael V Vitiello
Journal:  JAMA Neurol       Date:  2013-07       Impact factor: 18.302

8.  Cerebral perfusion and oxygenation differences in Alzheimer's disease risk.

Authors:  Adam S Fleisher; Katherine M Podraza; Katherine J Bangen; Curtis Taylor; Ayesha Sherzai; Kunal Sidhar; Thomas T Liu; Anders M Dale; Richard B Buxton
Journal:  Neurobiol Aging       Date:  2008-03-05       Impact factor: 4.673

9.  Methylene blue as a cerebral metabolic and hemodynamic enhancer.

Authors:  Ai-Ling Lin; Ethan Poteet; Fang Du; Roy C Gourav; Ran Liu; Yi Wen; Andrew Bresnen; Shiliang Huang; Peter T Fox; Shao-Hua Yang; Timothy Q Duong
Journal:  PLoS One       Date:  2012-10-09       Impact factor: 3.240

10.  Cerebral perfusion in relation to cognitive function and type 2 diabetes.

Authors:  A M Tiehuis; K L Vincken; E van den Berg; J Hendrikse; S M Manschot; W P T M Mali; L J Kappelle; G J Biessels
Journal:  Diabetologia       Date:  2008-05-17       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.